|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 27, 2015 ) Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
This report provides comprehensive information on the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and special features on late-stage and discontinued projects.
Complete report on Pipeline Review, H1 2015 for “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)” addition with 20 market data tables and 12 figures, spread across 46 pages is available at http://www.rnrmarketresearch.com/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2000 for a single user PDF license)
Scope:
• The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=365344 .
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics
More reports on Neurology therapeutics :
Global Neurodegenerative Diseases Market 2015-2019
According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely debilitating. They result in progressive degeneration of nerve cells, causing them to die eventually. These diseases cause ataxia and dementia in people, which can have a serious impact on the mental health of patients.
Complete report is available at http://www.rnrmarketresearch.com/global-neurodegenerative-diseases-market-2015-2019-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
